Fundamental Analysis of Nuvectis Pharma Inc - Growth / Value Index


NVCT - Valuation Highlights

Valuation Analysis

   Tremendous increasing in Book Value last 3 year
   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 7.54 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -4.62 -4.28 -5.02 %
Price to Book 6.85 7.84 -100.00 % 7.26
Price to Sales -25.23 0 0 %
Enterprise Value to EBITDA Multiple -2.80 -3.43 15.97 %


NVCT - Profitability Highlights

Profitability Analysis

   During the past twelve months, the company has given a strong Net Margin of 545.77%
   All key Trailing Twelve Months Margin growing by 15 %
   Tsr Profitability Index - Very Poor Score of 18.75
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -148.20 -0.126 100.00 % -29.75
Return On Asset -109.38 -116.41 100.00 % -21.16
Net Profit Margin 545.77 0 0 % 0
Operating Profit Margin 822.87 0 0 % 0
EBITDA Margin 815.36 0 0 % 0


Highlights
Market Cap112890 K
Enterprise Value93764.01 K
Price/Book TTM6.85
Outstanding Share18356.10 K
Float/ Outstanding Share35.07%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score2.66
Sloan Ratio-0.350
Peter Lynch Fair Value0


NVCT - Growth Highlights

Growth Analysis

   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 8.65
   Annual sales in last 3 years is trending down
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue -4101.00 K 100.00 % 100.00 %
Gross Profit -31394.00 K 15467.11 % 70.83 %
EBITDA -33438.00 K 17.02 % 32.77 %
Net Profit -22382.00 K 17.02 % 37.01 %
EPS -1.33 4.78 % NA


NVCT - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 95.00
   Altman Z Score of 3.64 suggests good Stability
   Company is Debt Free
   Net Debt zero balance-sheet with high liquidity
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0 0 % 0
Cash Ratio 2.74 -15.20 %
Quick Ratio 0 0 % 3.46
Shareholders Equity 92618.32 132835 %
Debt to EBITDA 0 0 %


Historical Valuation Ratios of Nuvectis Pharma Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Nuvectis Pharma Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Nuvectis Pharma Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Nuvectis Pharma Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)